On May 29, JMP Securities Silvan Tuerkcan revised the firm’s view on Taysha Gene Therapies, Inc. (NASDAQ:TSHA), raising the price target from $5 to $6 while keeping a Market Outperform rating. The update reflects the analyst’s optimistic review of the company’s latest clinical data and regulatory advancements.
Tuerkcan highlighted the endpoint’s compliance with FDA criteria and highlighted its neutrality in clinical trials as a benefit. With patients reaching an average of 2.2 milestones—above the 1+ milestone threshold to be considered a responder—the current data demonstrates a 100% response rate.
As the analyst notes, this is significant because natural history data show that without treatment, Rett syndrome patients usually do not observe improvements in milestones. That said, Taysha’s updates on both low and high dosages of their treatment show encouraging results, with an additional six patients showing improvements in high-dose updates.
Additionally, Tuerkcan’s report refers to possible corporate interest, pointing out that Astellas Pharma might submit a bid for TSHA-102—and possibly for Taysha Gene Therapies, Inc. in general—during the third quarter of 2025.
Read More: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds
Hedge Fund Resource Center